根据名称进行药物检索

Adderall XR 与 Azilect

Adderall XR 与 Azilect互相作用以及同时服用的可能性。

检测结果:

Adderall XR <> Azilect

现实性: 22.12.2023 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

使用沙吉兰一起安非他明可能会导致增加血压力。虽然这些影响预计不会有危险，在大多数人，有一种可能性高血压发生，这可能需要的医疗关注。谈谈你的医生之前使用这些药物在一起，如果你有一个历史的高血压、心脏病。你可能需要的剂量调整或更频繁的监测通过你的医生到安全地使用这两种药物。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

监视器：共同给予的非选择性的单胺氧化酶(卯)交感神经抑制剂和胺已经与相关联的严重高血压的反应。该机制涉及协同的交感神经的效果，由于增强降肾上腺素存储在肾上腺素能神经元(单胺氧化酶抑制剂的活动)和增强的解放，或降低重吸收儿茶酚胺(交感神经活性)。伴随使用的交感神经的药物是不允许在临床研究的雷沙吉兰。因为沙吉兰是选择性的毛-B抑制剂、高血压的反应将通常不能预期当使用与交感神经胺。然而，一种情况下的高血压的危机已经报告了在一个病人服用麻黄素的推荐剂量的不同选择性的毛-B抑制剂。在上市后时期，血压升高是报告中一个病人使用眼四氢唑啉下降，同时考虑推荐剂量的雷沙吉兰。

管理：谨慎建议，如果沙吉兰是结合使用交感神经胺。患有先前存在的高血压可能需要更多的经常监视他们的血压。

来源

Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31
Davies B, Bannister R, Sever P "Pressor amines and monoamine-oxidase inhibitors for treatment of postural hypotension in autonomic failure: limitations and hazards." Lancet 1 (1978): 172-5
Goulet JP, Perusse R, Turcotte JY "Contraindications to vasoconstrictors in dentistry: Part III. Pharmacologic interactions." Oral Surg Oral Med Oral Pathol 74 (1992): 692-7
Mason AM, Buckle RM ""Cold" cures and monoamine-oxidase inhibitors." Br Med J 1 (1969): 845-6
Smookler S, Barmudez AJ "Hypertensive crisis resulting from an MAO inhibitor and an over-the counter appetite suppressant." Ann Emerg Med 11 (1982): 482-4
Cuthbert MF, Greenberg MP, Morley SW "Cough and cold remedies: a potential danger to patients on monoamine oxidase inhibitors." Br Med J 1 (1969): 404-6
Horler AR, Wynne NA "Hypertensive crisis due to pargyline and metaraminol." Br Med J 5459 (1965): 460-1
Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
"Product Information. Vyvanse (lisdexamfetamine)." Shire US Inc, Florence, KY.
Schildkraut JJ, Klerman GL, Friend DG, Greenblatt M "Biochemical and pressor effects of oral d,l-dihydroxyphenylalanine in patients pretreated with antidepressant drugs." Ann N Y Acad Sci 107 (1963): 1005-15
Lefebvre H, Noblet C, Morre N, Wolf LM "Pseudo-phaeochromocytoma after multiple drug interactions involving the selective monoamine oxidase inhibitor selegiline." Clin Endocrinol (Oxf) 42 (1995): 95-8
Humberstone PM "Hypertension from cold remedies." Br Med J 1 (1969): 846
Smookler S, Bermudez AJ "Hypertensive crisis resulting from an MAO inhibitor and an over-the-counter appetite suppressant." Ann Intern Med 11 (1982): 482-4
Elis J, Laurence DR, Mattie H, Prichard BN "Modification by monoamine oxidase inhibitors of the effect of some sympathomimetics on blood pressure." Br Med J 2 (1967): 75-8
Markowitz JS, Patrick KS "Pharmacokinetic and pharmacodynamic drug interactions in the treatment of attention-deficit hyperactivity disorder." Clin Pharmacokinet 40 (2001): 753-72
Goldberg LI "Monoamine oxidase inhibitors: adverse reactions and possible mechanisms." JAMA 190 (1964): 456-62
Harrison WM, McGrath PJ, Stewart JW, Quitkin F "MAOIs and hypertensive crises: the role of OTC drugs." J Clin Psychiatry 50 (1989): 64-5
Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Pritchard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5
"Product Information. Azilect (rasagiline)." Teva Pharmaceuticals USA, North Wales, PA.
Boakes AJ, Laurence DR, Teoh PC, Barar FS, Benedikter LT, Prichard BN "Interactions between sympathomimetic amines and antidepressant agents in man." Br Med J 1 (1973): 311-5
Ban TA "Drug interactions with psychoactive drugs." Dis Nerv Syst 36 (1975): 164-6
Wright SP "Hazards with monoamine-oxidase inhibitors: a persistent problem." Lancet 1 (1978): 284-5
Dally PJ "Fatal reaction associated with tranylcypromine and methylamphetamine." Lancet 1 (1962): 1235-6
Krisko I, Lewis E, Johnson JE "Severe hyperpyrexia due to tranylcypromine-amphetamine toxicity." Ann Intern Med 70 (1969): 559-64
Sjoqvist F "Psychotropic drugs (2) interaction between monoamine oxidase (MAO) inhibitors and other substances." Proc R Soc Med 58 (1965): 967-78